Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) tinted loss of -0.39% (-0.04 points) to US$10.09. The volume of 0.22 Million shares climbed down over an trading activity of 228.92 Million shares. EPS ratio determined by looking at last 12 month figures is -1.83. Over the same time span, the stock marked US$12 as its best level and the lowest price reached was US$2.81. The corporation has a market cap of US$216.13 Million.
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -54.8 percent while most common profitability ratio return on investment (ROI) was -55 percent. The company’s institutional ownership is monitored at 51.6 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.6. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Renasant Corporation (NASDAQ:RNST) is worth US$2.39 Billion and has recently fallen -0.4% to US$47.63. The latest exchange of 0.19 Million shares is below its average trading activity of 153.64 Million shares. The day began at US$47.7 but the price moved to US$47.44 at one point during the trading and finally capitulating to a session high of US$48.12. The stock tapped a 52-week high of US$49.78 while the mean 12-month price target for the shares is US$47.71.
Currently, the stock carries a price to earnings ratio of 19.75, a price to book ratio of 1.53, and a price to sales ratio of 6.07. For the past 5 years, the company’s revenue has grown 18.7%, while the company’s earnings per share has grown 16.5%. With an institutional ownership near 69.1%, it carries an earnings per share ratio of 2.41.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 4 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.67.